Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of MNV-BM-PLC in Primary Mitochondrial Diseases
NCT04548843Phase 1Withdrawn
- Sponsor
- Minovia Therapeutics
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MNV-BM-PLC in primary mitochondrial disease (PMD), sponsored by Minovia Therapeutics. Primary endpoints: Number of participants with Treatment-related adverse events as assessed by CTCAE v5.0 at 1 month, Measurement of hemoglobin level at 1 month and 2 more. Planned start Mar 2022; status: withdrawn.
02
Drugs
MNV-BM-PLC
03
Conditions
primary mitochondrial disease (PMD)
Beyond the preview
Go deeper on NCT04548843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548843.